{Reference Type}: Journal Article
{Title}: Prognostic significance of MATR3 in stage I and II non-small cell lung cancer patients.
{Author}: Durślewicz J;Klimaszewska-Wiśniewska A;Jóźwicki J;Antosik P;Kozerawski K;Grzanka D;Braun M;
{Journal}: J Cancer Res Clin Oncol
{Volume}: 0
{Issue}: 0
{Year}: Jun 2022 20
{Factor}: 4.322
{DOI}: 10.1007/s00432-022-04097-9
{Abstract}: <B>OBJECTIVE: </B>Matrin 3 (MATR3) is a nuclear matrix protein involved in mRNA stabilization, nuclear retention of hyper-edited RNAs, and RNA splicing. The role of MATR3 in cancer is still unclear. The present study aimed to investigate expression levels and prognostic significance of MATR3 in stage I and II non-small cell lung cancer (NSCLC) patients.<BR><B>METHODS: </B>We examined MATR3 protein immunohistochemically in tumoral and non-tumoral tissue sections from n = 67 NSCLC patients treated at hospital, and MATR3 mRNA from The Cancer Genome Atlas (TCGA) cohort with respect to valid prognostic and predictive features, as well as treatment outcome.<BR><B>RESULTS: </B>Significantly higher immunohistochemical levels of MATR3 protein were found in tumor-adjacent tissue compared to cancer (p = 0.049). A decrease in MATR3 protein expression was found to be a significant independent adverse prognostic factor for patients overall survival (p = 0.007). By contrast, we observed higher MATR3 mRNA levels in tumoral tissue compared to control lung tissues (p < 0.001). Based on the TCGA dataset, we reported that high MATR3 mRNA level was significantly associated with worse OS of NSCLC patients (p < 0.001); however, it was not an independent prognostic marker (p = 0.156). The discrepancies in prognostic significance of MATR3 gene mRNA and protein levels imply a need for further investigation.<BR><B>CONCLUSIONS: </B>In conclusion, the present study warrants further investigation into the biological and prognostic value of MATR3 as a potential prognostic marker in early-stage NSCLC patients.